Lisofylline

Lisofylline

SCHEMBL6876201

[2H]c1nc2c(c(=O)n(CCCC([2H])([2H])[C@@H](O)C([2H])([2H])[2H])c(=O)n2C)n1C

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 6/20 0.50
TNF P01375 4/20 0.50
LMNA P02545 2/20 0.50
CYP1A2 P05177 2/20 0.50
NFKB1 P19838 2/20 0.50
ACHE P22303 2/20 0.50
PDE4A P27815 2/20 0.50
PMP22 Q01453 2/20 0.50
USP2 O75604 1/20 0.50
TSHR P16473 1/20 0.50
PDE4B Q07343 1/20 0.50
PDE4C Q08493 1/20 0.50
PDE4D Q08499 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
CHIT1 Q13231 1/20 0.43
CHIA Q9BZP6 1/20 0.43
AKR1B1 P15121 1/20 0.42
BLM P54132 2/20 0.42
ESR1 P03372 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lisofylline SCHEMBL6876196 1.00 ADORA2B (0.50) ADORA2BTNFLMNACYP1A2NFKB1
Lisofylline SCHEMBL173557 1.00 ADORA2B (0.50) ADORA2BTNFLMNACYP1A2NFKB1
Lisofylline SCHEMBL13695588 0.95 ADORA2B (0.48) ADORA2BTNFLMNACYP1A2NFKB1
Lisofylline SCHEMBL13695587 0.95 ADORA2B (0.48) ADORA2BTNFLMNACYP1A2NFKB1
Lisofylline SCHEMBL13695586 0.95 ADORA2B (0.48) ADORA2BTNFLMNACYP1A2NFKB1
Lisofylline SCHEMBL6877342 0.93 ADORA2B (0.52) ADORA2BTNFLMNACYP1A2NFKB1
Lisofylline SCHEMBL6878416 0.93 ADORA2B (0.52) ADORA2BTNFLMNACYP1A2NFKB1
Lisofylline SCHEMBL6877052 0.93 ADORA2B (0.52) ADORA2BTNFLMNACYP1A2NFKB1
Pcs-499 SCHEMBL173235 0.91 ADORA2B (0.62) ADORA2BTNFLMNACYP1A2NFKB1
Lisofylline SCHEMBL6876106 0.91 ADORA2B (0.62) ADORA2BTNFLMNACYP1A2NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263601-B2 Deuterium substituted xanthine derivatives CONCERT PHARMACEUTICALS, INC. (US) 2012-09-11 US disclosed
US-20110077255-A1 SUBSTITUTED XANTHINE DERIVATIVES CONCERT PHARMACEUTICALS, INC. 2011-03-31 US disclosed
US-20110053961-A1 SUBSTITUTED XANTHINE DERIVATIVES CONCERT PHARMACEUTICALS, INC. 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077255-A1 SUBSTITUTED XANTHINE DERIVATIVES XDH, HPRT1, CXCR3 ADORA2B 60/4885TNF 583/4885LMNA 2823/4885
US-20110053961-A1 SUBSTITUTED XANTHINE DERIVATIVES XDH, HPRT1, CXCR3 ADORA2B 60/4885TNF 583/4885LMNA 2823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.